My thoughts:

"ongoing discussions" = locked and unblinded late last week

subject matter of discussions:
- EUA vs full approval
- distribution considerations - targeted patient populations in step-wise fashion similar to vaccines, present supply and how quickly will needed amount come online, which countries, sales force, etc.
- financing
- price
- FDA announcement details and timing
- what is NOT being discussed at length are the results, since they are stellar and statistically significant IMO

Thank you shorts for putting CYDY on sale one last time